Relmacabtagene Autoleucel in Hematologic Malignancies

Sponsor
Shanghai Ming Ju Biotechnology Co., Ltd.
Study ID
NCT06142188
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Relmacabtagene Autoleucel — BIOLOGICAL
    A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells

Study Details

To evaluate the efficacy and safety of Relmacabtagene Autoleucel in the treatment of adult patients with hematologic malignancies in real-world

Key Dates

First listed
Nov 21, 2023
Start date
Dec 28, 2023
Status verified
Nov 2023
Primary completion
Dec 31, 2038
Completion
Dec 31, 2038

Study Design

Enrollment
150 participants (estimated)

Arms

  • Arm: Relmacabtagene Autoleucel
    Relmacabtagene Autoleucel administered as a single IV infusion at a target dose of 1 x 10\^8 anti-cluster of differentiation (CD)19 chimeric antigen receptor (CAR) transduced autologous T cells on Day1.

Primary Outcome Measure

ORR [ Time Frame: 15 years ]

Central Contacts

Related Studies